Table 1.
Clinical Trials of In Situ Adenoviral Gene Therapy Single Agents for Prostate Cancer
| NIH No. | Phase | Indication | Promoter | Therapeutic |
| 9601-144 | I | Local recurrent | RSV | HSV-TK |
| 9705-187 | I | Neoadjuvant | RSV | HSV-TK |
| 9706-192 | I | Local recurrent | CMV | p53 |
| 9710-217 | I | Neoadjuvant | CMV | p53 |
| 9801-229 | I | Neoadjuvant | RSV | HSV-TK |
| 9802-236 | I | Local recurrent | PSA/PSE | Replication (E1A) |
| 9812-276 | I | Metastatic or recurrent | Murine OC | HSV-TK |
| 9906-321 | I | Local recurrent | CMV | Replication + CD/HSV-TK |
| 9909-338 | I | Neoadjuvant | RSV | CDKN2A |
| 9910-344 | I/II | Local recurrent | Rat probasin and PSA/PSE | Replication (E1A and E1B) |
| 0010-426 | I | Metastatic | Murine OC | Replication (E1A) |
| 0010-428 | I | Neoadjuvant | CMV | Replication + CD/HSV-TK |
| 0101-449 | I | Local recurrent | CMV | IL-12 |
| 0203-517 | I | Neoadjuvant | CMV | IFN-β |
| 0204-533 | I | Local recurrent | CMV | NIS |
| 0309-601 | I | Local recurrent | RSV | IL-12 |
| 0309-603 | I | Neoadjuvant | CMV | TRAIL |
NIH, National Institutes of Health; RSV, Rouse sarcoma virus (constitutively active); HSV-TK, herpes simplex virus thymidine kinase; CMV, cytomegalovirus (constitutively active); PSA/PSE, prostate-specific antigen promoter/enhancer;CDKN2A, cyclin-dependent kinase inhibitor 2A; OC, osteocalcin; IL-12, interleukin 12; IFN-β, interferon-β; NIS, sodium iodide symporter; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand. Local recurrent, after radiation therapy; Neoadjuvant, before radical prostatectomy, Data derived from http://www.gemcris.od.nih.gov.